SG10201604279TA - Dual targeting - Google Patents
Dual targetingInfo
- Publication number
- SG10201604279TA SG10201604279TA SG10201604279TA SG10201604279TA SG10201604279TA SG 10201604279T A SG10201604279T A SG 10201604279TA SG 10201604279T A SG10201604279T A SG 10201604279TA SG 10201604279T A SG10201604279T A SG 10201604279TA SG 10201604279T A SG10201604279T A SG 10201604279TA
- Authority
- SG
- Singapore
- Prior art keywords
- dual targeting
- targeting
- dual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ecology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11004373 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201604279TA true SG10201604279TA (en) | 2016-07-28 |
Family
ID=46207961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604279TA SG10201604279TA (en) | 2011-05-27 | 2012-05-29 | Dual targeting |
| SG2013087945A SG195196A1 (en) | 2011-05-27 | 2012-05-29 | Dual targeting |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013087945A SG195196A1 (en) | 2011-05-27 | 2012-05-29 | Dual targeting |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20140206846A1 (en) |
| EP (1) | EP2726510B1 (en) |
| JP (2) | JP2014516542A (en) |
| CN (2) | CN103930445B (en) |
| AU (1) | AU2012265156B2 (en) |
| CA (1) | CA2853383C (en) |
| DK (1) | DK2726510T3 (en) |
| ES (1) | ES2943577T3 (en) |
| FI (1) | FI2726510T3 (en) |
| HR (1) | HRP20230411T1 (en) |
| HU (1) | HUE061692T2 (en) |
| IL (1) | IL229649B (en) |
| LT (1) | LT2726510T (en) |
| PL (1) | PL2726510T3 (en) |
| PT (1) | PT2726510T (en) |
| RS (1) | RS64179B1 (en) |
| SG (2) | SG10201604279TA (en) |
| SI (1) | SI2726510T1 (en) |
| WO (1) | WO2012163520A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2928920A1 (en) * | 2012-12-05 | 2015-10-14 | Dutalys GmbH | Dual targeting |
| RU2020129339A (en) * | 2013-12-20 | 2020-10-02 | Дженентек, Инк. | ANTIBODIES WITH DUAL SPECIFICITY |
| CN106661119A (en) | 2014-07-01 | 2017-05-10 | 辉瑞公司 | Bispecific heterodimeric diabodies and uses thereof |
| MX2017004076A (en) | 2014-09-29 | 2017-07-04 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm. |
| US11071783B2 (en) | 2015-03-19 | 2021-07-27 | Duke University | HIV-1 neutralizing antibodies and uses thereof |
| WO2016149698A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies) |
| WO2016149695A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES) |
| CA2979708A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
| WO2018060035A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Spr-based dual-binding assay for the functional analysis of multispecific molecules |
| EP3330289A1 (en) | 2016-12-02 | 2018-06-06 | Friedrich-Alexander-Universität Erlangen-Nürnberg | A cd33-, cd16- and cd123-specific single chain triplebody |
| GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
| MX2020009152A (en) * | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof. |
| SG11202106198YA (en) * | 2018-12-21 | 2021-07-29 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use |
| JP7241888B2 (en) | 2018-12-30 | 2023-03-17 | エフ． ホフマン－ラ ロシュ アーゲー | Binding assay based on pH gradient SPR |
| EP3948281A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Spr-based binding assay for the functional analysis of multivalent molecules |
| EP3947440A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for generating avid-binding multispecific antibodies |
| CN114008081A (en) | 2019-06-19 | 2022-02-01 | 豪夫迈·罗氏有限公司 | Method for generating bivalent bispecific antibody-expressing cells by targeted integration of multiple expression cassettes in defined tissue format |
| BR112021025425A2 (en) | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Method for producing a recombinant mammalian cell and use of cre recombinase mRNA |
| AU2020297940A1 (en) | 2019-06-19 | 2021-12-16 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| MX2021015648A (en) | 2019-06-19 | 2022-02-03 | Hoffmann La Roche | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization. |
| CN114008212A (en) | 2019-06-19 | 2022-02-01 | 豪夫迈·罗氏有限公司 | Method for generating trivalent antibody expressing cells by targeted integration of multiple expression cassettes in a defined tissue format |
| JP7450647B2 (en) | 2019-06-26 | 2024-03-15 | エフ． ホフマン－ラ ロシュ アーゲー | Mammalian cell line with SIRT-1 gene knockout |
| JP2022553640A (en) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | Methods of treating eye disorders |
| WO2021084104A1 (en) | 2019-10-30 | 2021-05-06 | Bioinvent International Ab | Tetravalent antibody molecules |
| EP4085254B1 (en) | 2020-01-02 | 2024-06-05 | F. Hoffmann-La Roche AG | Ada-response specification assay |
| EP4126940A1 (en) | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Antibody that binds to vegf and pdgf-b and methods of use |
| KR20230061458A (en) | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Antibodies that bind to VEGF-A and ANG2 and methods of use |
| IL301366A (en) | 2020-09-24 | 2023-05-01 | Hoffmann La Roche | Mammalian cell lines with gene knockout |
| CN116670282A (en) | 2020-12-22 | 2023-08-29 | 豪夫迈·罗氏有限公司 | XBP 1-targeting oligonucleotides |
| WO2022175217A1 (en) | 2021-02-18 | 2022-08-25 | F. Hoffmann-La Roche Ag | Method for resolving complex, multistep antibody interactions |
| EP4320444A1 (en) | 2021-04-09 | 2024-02-14 | F. Hoffmann-La Roche AG | Process for selecting cell clones expressing a heterologous polypeptide |
| WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
| WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
| WO2023217933A1 (en) | 2022-05-11 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and il6 and methods of use |
| WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
| WO2024079069A1 (en) | 2022-10-12 | 2024-04-18 | F. Hoffmann-La Roche Ag | Method for classifying cells |
| WO2024110426A1 (en) | 2022-11-23 | 2024-05-30 | F. Hoffmann-La Roche Ag | Method for increasing recombinant protein expression |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| PE20020132A1 (en) | 2000-06-29 | 2002-03-04 | Abbott Lab | DOUBLE SPECIFICITY ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF |
| JP4303105B2 (en) * | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | Dual specific ligands and their use |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7749724B2 (en) | 2005-07-05 | 2010-07-06 | Washington State University | Fluorogenic selective and differential medium for isolation of Enterobacter sakazakii |
| WO2007112940A2 (en) | 2006-03-31 | 2007-10-11 | Ablynx N.V. | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
| DK2059533T3 (en) | 2006-08-30 | 2013-02-25 | Genentech Inc | MULTI-SPECIFIC ANTIBODIES |
-
2012
- 2012-05-29 US US14/122,758 patent/US20140206846A1/en not_active Abandoned
- 2012-05-29 SG SG10201604279TA patent/SG10201604279TA/en unknown
- 2012-05-29 DK DK12725311.0T patent/DK2726510T3/en active
- 2012-05-29 ES ES12725311T patent/ES2943577T3/en active Active
- 2012-05-29 RS RS20230337A patent/RS64179B1/en unknown
- 2012-05-29 AU AU2012265156A patent/AU2012265156B2/en active Active
- 2012-05-29 HR HRP20230411TT patent/HRP20230411T1/en unknown
- 2012-05-29 HU HUE12725311A patent/HUE061692T2/en unknown
- 2012-05-29 EP EP12725311.0A patent/EP2726510B1/en active Active
- 2012-05-29 CA CA2853383A patent/CA2853383C/en active Active
- 2012-05-29 SI SI201232028T patent/SI2726510T1/en unknown
- 2012-05-29 LT LTEPPCT/EP2012/002279T patent/LT2726510T/en unknown
- 2012-05-29 PL PL12725311.0T patent/PL2726510T3/en unknown
- 2012-05-29 JP JP2014513080A patent/JP2014516542A/en not_active Withdrawn
- 2012-05-29 WO PCT/EP2012/002279 patent/WO2012163520A1/en active Application Filing
- 2012-05-29 FI FIEP12725311.0T patent/FI2726510T3/en active
- 2012-05-29 CN CN201280037640.9A patent/CN103930445B/en active Active
- 2012-05-29 SG SG2013087945A patent/SG195196A1/en unknown
- 2012-05-29 PT PT127253110T patent/PT2726510T/en unknown
- 2012-05-29 CN CN202011214419.9A patent/CN112661848A/en active Pending
-
2013
- 2013-11-27 IL IL229649A patent/IL229649B/en active IP Right Grant
-
2017
- 2017-06-09 US US15/618,724 patent/US20180094078A1/en not_active Abandoned
- 2017-07-06 JP JP2017132795A patent/JP6659626B2/en active Active
-
2020
- 2020-04-28 US US16/860,418 patent/US20210079119A1/en not_active Abandoned
-
2023
- 2023-05-15 US US18/317,385 patent/US20230279155A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL229649B (en) | 2019-08-29 |
| ES2943577T3 (en) | 2023-06-14 |
| JP2017221200A (en) | 2017-12-21 |
| CA2853383C (en) | 2021-04-06 |
| US20180094078A1 (en) | 2018-04-05 |
| CN103930445B (en) | 2021-03-09 |
| JP2014516542A (en) | 2014-07-17 |
| SI2726510T1 (en) | 2023-06-30 |
| US20140206846A1 (en) | 2014-07-24 |
| US20230279155A1 (en) | 2023-09-07 |
| AU2012265156B2 (en) | 2017-01-19 |
| CN103930445A (en) | 2014-07-16 |
| EP2726510A1 (en) | 2014-05-07 |
| DK2726510T3 (en) | 2023-05-15 |
| WO2012163520A4 (en) | 2013-01-24 |
| US20210079119A1 (en) | 2021-03-18 |
| PL2726510T3 (en) | 2023-05-29 |
| SG195196A1 (en) | 2013-12-30 |
| WO2012163520A1 (en) | 2012-12-06 |
| AU2012265156A1 (en) | 2014-01-16 |
| IL229649A0 (en) | 2014-01-30 |
| EP2726510B1 (en) | 2023-03-08 |
| JP6659626B2 (en) | 2020-03-04 |
| HUE061692T2 (en) | 2023-08-28 |
| FI2726510T3 (en) | 2023-05-04 |
| LT2726510T (en) | 2023-05-10 |
| CA2853383A1 (en) | 2012-12-06 |
| RS64179B1 (en) | 2023-05-31 |
| NZ619409A (en) | 2016-05-27 |
| CN112661848A (en) | 2021-04-16 |
| HRP20230411T1 (en) | 2023-07-07 |
| PT2726510T (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL229649A0 (en) | Dual targeting | |
| IL236563A0 (en) | Search-powered connection targeting | |
| DK3798230T3 (en) | Terapeutiske antistoffer | |
| EP2755962A4 (en) | Azaindazoles | |
| EP2715659A4 (en) | Überfeed | |
| EP2754063A4 (en) | Smb2 scaleout | |
| PL3219801T3 (en) | Construct | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| EP2695208A4 (en) | Micro-thermocouple | |
| ZA201304139B (en) | Combination | |
| PL2606715T3 (en) | Baler-wrapper combination | |
| EP2679138A4 (en) | Endsoscope | |
| EP2708561A4 (en) | Bio-pin | |
| DK2770906T3 (en) | Applanationstonometer | |
| EP2684382A4 (en) | Earpuff | |
| EP2698098A4 (en) | Campimeter | |
| EP2694655A4 (en) | pAVEC | |
| HK1211953A1 (en) | Dual targeting | |
| EP2702929A4 (en) | Campimeter | |
| EP2672969A4 (en) | Combination | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5031P (en) | BESYS Beschorneria yuccoides | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| IL213949A0 (en) | Aerial targeting |